Diuretics Part 1: Loop Diuretics and Thiazides

The proximal convoluted tubule reabsorbs roughly 65% of filtered sodium, driven by the sodium-hydrogen exchanger isoform 3 on the luminal surface working with carbonic anhydrase to couple sodium reabsorption to bicarbonate reclamation. Carbonic anhydrase inhibitors act at this site, though it is not the primary target of loop diuretics or thiazides.

The thick ascending limb reabsorbs approximately 25% of filtered sodium via the sodium-potassium-2-chloride cotransporter isoform 2 (the Na-K-2Cl cotransporter). This segment is impermeable to water, so sodium reabsorption here without accompanying water is what builds the hypertonic medullary interstitium required for antidiuretic hormone-dependent urinary concentration. When the Na-K-2Cl cotransporter is blocked by loop diuretics, the medullary gradient collapses and a large volume of isotonic fluid floods the more distal tubular segments — producing the most powerful natriuresis achievable with any diuretic class.

The distal convoluted tubule handles 5 to 8% of filtered sodium through the electroneutral sodium-chloride cotransporter, the target of thiazide diuretics. Because the fractional sodium delivery here is smaller, thiazide-induced natriuresis is more modest than loop-diuretic natriuresis — but this makes thiazides well suited for sustained outpatient blood pressure control. The collecting duct handles only 2 to 3% of sodium via the epithelial sodium channel, regulated by aldosterone and targeted by potassium-sparing diuretics.

By blocking the sodium-chloride cotransporter, thiazides reduce intracellular sodium in the distal convoluted tubule cell. This enhances basolateral sodium-calcium exchange, which draws calcium into the cell from the tubular lumen through the apical calcium channel known as TRPV5. The net result is calcium retention in the body — the opposite of loop diuretics, which promote urinary calcium loss. This mechanism underlies the clinical use of thiazides in reducing stone recurrence in calcium nephrolithiasis and their contraindication in hypercalcemia.

Chlorthalidone is a thiazide-like agent with a half-life of 40 to 60 hours, far exceeding hydrochlorothiazide's 6 to 15 hours. This longer duration provides more consistent 24-hour blood pressure coverage. The ALLHAT trial demonstrated that chlorthalidone-based therapy reduced cardiovascular events more effectively than amlodipine- or lisinopril-based therapy in high-risk hypertensive patients, establishing it as the guideline-preferred agent for most patients with hypertension.

Metolazone retains diuretic efficacy even at glomerular filtration rates below 30 milliliters per minute, where conventional thiazides and hydrochlorothiazide lose effectiveness. This is attributed partly to a proximal tubular action. In clinical practice, metolazone is used almost exclusively as an add-on agent to loop diuretics in diuretic-resistant volume overload, exploiting sequential nephron blockade. The combination can produce dramatic natriuresis and requires electrolyte and renal function monitoring within 24 to 48 hours of initiation.

Loop diuretics are the standard of care for symptomatic volume overload in heart failure. Intravenous furosemide provides faster and more reliable natriuresis than oral therapy in acute decompensated heart failure, particularly when bowel wall edema impairs oral absorption. The DOSE trial established that high-dose intravenous furosemide at 2.5 times the total oral daily dose was not inferior to low-dose therapy and produced greater net fluid loss and more rapid symptom relief — supporting dose escalation rather than conservative dosing in the acute setting.

Chlorthalidone is the preferred thiazide-class agent for hypertension based on ALLHAT outcome data. For resistant hypertension, the PATHWAY-2 trial demonstrated that spironolactone added as a fourth agent outperformed bisoprolol and doxazosin in reducing blood pressure, establishing mineralocorticoid receptor antagonism as the preferred fourth-line strategy.

Acute hypercalcemia is managed with aggressive intravenous saline to restore intravascular volume and promote calciuresis, followed by loop diuretics to sustain calcium excretion. Thiazides are absolutely contraindicated in hypercalcemia because they reduce urinary calcium and would worsen the condition. For calcium nephrolithiasis, thiazides reduce urinary calcium excretion by 30 to 50% and are a first-line pharmacological strategy for stone recurrence prevention. High fluid intake must accompany thiazide therapy for nephrolithiasis, as the protective benefit depends on high urine volume as well as reduced calcium concentration.

Nonsteroidal anti-inflammatory drugs attenuate the natriuretic response to both loop and thiazide diuretics by inhibiting cyclooxygenase-dependent prostaglandin synthesis. Renal prostaglandins normally oppose tubular sodium reabsorption and dilate the afferent arteriole to maintain glomerular filtration rate. Removing this tone reduces glomerular filtration rate and blunts the diuretic response — a clinically significant interaction frequently overlooked when patients self-medicate with over-the-counter nonsteroidal anti-inflammatory drugs.

Lithium toxicity is a well-established complication of diuretic use. Both classes trigger compensatory upregulation of sodium-hydrogen exchanger-mediated reabsorption in the proximal convoluted tubule, which reabsorbs lithium along with sodium. Thiazides can double or triple lithium plasma concentrations within days of initiation. When a diuretic is required in a lithium-treated patient, amiloride is preferred because it does not promote proximal lithium reabsorption. Digoxin toxicity risk is amplified by diuretic-induced hypokalemia and hypomagnesemia, as both cations normally compete with digoxin for sodium-potassium-ATPase binding; their depletion lowers the toxic threshold.